Reuters recently reported that a growing number of U.S. cardiologists are expressing frustration with the lack of availability of newer cardiac devices in the United States as compared to Europe. Their beef: U.S. patients have to wait longer for access to beneficial next generation therapies.
Medtech storytelling in the era of comparative effectiveness
For those of us who live and breathe healthcare and medtech, the market’s move toward comparative effectiveness is really no surprise. Its drivers abound.
There’s the exceedingly slow global economic recovery and an ever-aging, longer-living patient population. The Patient Portable and Affordable Care Act has the U.S. healthcare market in fundamental transition, with purchase decision-making becoming less about physician preference and more about the C-suite’s bottom line.